here's the opening paragraph.. sums up article
Bear Thesis On Trius Therapeutics Seems Flawed
By Jason Napodano, CFA & Aafia Chaudhry, MD
Shares of Trius Therapeutics (NASDAQ:TSRX) have been under pressure over the past three months, down nearly 30% from the highs in mid-September 2012. We decided to delve into why the shares are down over this period by putting on our bear-caps and coming up with reasons to sell the stock. We came up with several reasons, although none seems truly a concern validated by existing fundamentals or valuation. In fact, the single best reason we found seems to be a short-term event that, in our opinion, has created a unique buying opportunity. Below we discuss each reason and then provide the counterpoint bullish argument.